康艾注射液在晚期非小细胞肺癌化疗中的增强作用

Kaugai injection＇s enhancement in patients with advanced non-small cell l.tmg cancer

目的研究康艾注射液在Ⅲ期、Ⅳ期非小细胞肺癌（NSCLC）化疗中的作用。方法经病理组织学或细胞学检查确诊的Ⅲ期、Ⅳ期NSCLC患者随机分为试验组和对照组。试验组144例采取康艾注射液联合盖诺、顺铂化疗，对照组142例，只采用盖诺、顺铂化疗。每3周为1个周期，化疗4个周期。每2个周期评价疗效，监测治疗前后患者肝肾功能、胃肠道反应、血常规和血清免疫球蛋白（Ig）含量变化。结果试验组和对照组的有效率分别是49．3％和45．7％（p〉0．05），疾病进展（PD）率分别是6．9％和15．5％（p〈0．05）。试验组胃肠道反应好、骨髓抑制较对照组减轻，差异有统计学意义（p〈O．05）；iit验组和对照组治疗前血清IsA、IgG和IgM含量无明显差异，治疗后试验组患者的血清IgG含量（18．97±4．75）g／L、IgM含量（1．43±0．28）g/L较对照组明显升高，差异有统计学意义（P〈O．05）；试验组治疗后KPS评分明显高于对照组（p〈O．01）。结论康艾注射液联合盖诺、顺铂方案治疗Ⅲ期、Ⅳ期NSCLC患者，可使患者KPS评分提高，保护造血功能，提高免疫力，减少胃肠道反应的发生，改善生活质量，明显起到辅助、增效作用。

Objective：To study the role of the Kangai injection in stage Ⅲ,Ⅳ stage non-small cell lung cancer （NSCLC） Chemotherapy. Methods： By pathology or cytology confirmed stage Ⅲ,Ⅳ stage NSCLC patients were randomly divided into the experi- mental and the control groups, the experimental group including 144 patients was treated by Kangai injection combined with vinorelbine and eisplatin chemotherapy, the control group including 142 patients,was only treated by vinorelbine and eisplatin chemotherapy.Every 3 weeks for a period,the groups were treated for 4 cycles of chemotherapy.and evaluated every 2 cycles by monitoring liver and renal function, gastrointestinal reactions, blood and serum immunoglobulin （Ig） content before and after treatment. Results： The efficiency rates of the two groups were 49.3% and 45.7% （p〉 0.05）, the disease progression rates were 6.9% and 15.5%（p〈0.05）the gastrointestinal reaction of the the experimental group was better than the control group and the bone marrow suppression reduced, the difference was statistically sig- nificant （p〈O.05）.the two groups＇ levels before treatment of serum IgA, IgG and IgM showed no significant difference,the experimental group after treatment, serum IgO concentration （18.97 ± 4.75） g / L, IgM levels （1.43 ± 0.28） g / L was significantly higher than the con- trol group, the difference was statistically significant （p 〈0.05）, KPS score of the experimental group after treatment group was significantly higher than the control group （p 〈0.01）. Conclusions： Kangai injection combined with vinorelbine and cisplatin in the treatment of stage Ⅲ,Ⅳ stage NSCLC patients can improve KPS score of patients, protect hematopoietic function, improve immunity, reduce the incidence of gastrointestinal reactions and improve the quality of life, obviously play a supporting, synergistic effect.